



20.03.2024

11:30 - 13:00 **Type: Industry Satellite Symposium** **Forum**
Title: MSD - Clinical perspectives on the treatment evolution of **Hall**
resectable early-stage NSCLC

11:30 - 11:35 **Welcome and opening remarks**

Joachim Aerts, Erasmus MC - University Medical Center, Rotterdam, Netherlands

11:35 - 12:00 **Rationale of new systemic treatment options and overview of clinical trials in resectable early-stage NSCLC**

Joachim Aerts, Erasmus MC - University Medical Center, Rotterdam, Netherlands

12:00 - 12:20 **Implementation of new treatment options in resectable early-stage NSCLC: Thoracic Surgeon's view**

Mir Hoda, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria

12:20 - 12:35 **Role of biomarker testing and evaluation of response to systemic treatments in early-stage NSCLC: Pathologist's view**

Keith Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, United Kingdom

12:35 - 12:55 **Patient cases and practice of multidisciplinary tumor boards**

12:55 - 13:00 **Closing remarks**

Mir Hoda, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria



11:30 - 12:30	Type: Industry Satellite Symposium Title: Novocure GmbH - Tumor treating fields therapy: A force for change in lung cancer Moderation: Maurice Perol, France	South Hall 2
11:30 - 11:35	Welcome and introduction <u>Maurice Perol</u> , Centre Léon Bérard, Lyon, France	
11:35 - 11:50	The scientific basis of TTFields <u>Rami El Shafie</u> , Universitätsmedizin Göttingen, Goettingen, Germany	
11:50 - 12:05	The clinical evidence behind TTFields therapy in NSCLC <u>Rupesh Kotecha</u> , Miami Cancer Institute - Baptist Health South Florida, Miami, United States of America	
12:05 - 12:20	The future of TTFields therapy in NSCLC <u>Giovanni Luca Ceresoli</u> , ASST Valle Olona, Busto Arisizio, Italy	
12:20 - 12:28	Panel discussion	
12:28 - 12:30	Closing remarks <u>Maurice Perol</u> , Centre Léon Bérard, Lyon, France	
13:00 - 13:30	Type: Coffee break Title: Welcome reception	Congress Hall Foyer
13:30 - 14:15	Type: Keynote lecture Title: Opening session and Heine H. Hansen Award Moderation: Natasha Leighl, Canada; Paul Baas, Netherlands	Congress Hall
13:30 - 13:45	Welcome to the European Lung Cancer Congress 2024 by the Scientific Co-Chairs <u>Natasha Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada	
13:45 - 13:50	Introduction to the Heine H. Hansen Award 2024 <u>Paul Baas</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
13:50 - 14:15	Advancing precision oncology in lung cancer: A multidisciplinary-driven approach <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital, Barcelona, Spain	



14:30 - 16:00 **Type: Educational session** **Forum Hall**
Title: TNM classification: 9th edition and transition to 10th
Moderation: Paul van Schil, Belgium; Hisao Asamura, Japan

14:30 - 14:50 **Lung cancer**
Ramon Rami-Porta, Hospital Mutua de Terrassa, Terrassa, Spain

14:50 - 15:10 **Thymic epithelial tumours**
Enrico Ruffini, University of Turin, Torino, Italy

15:10 - 15:30 **Mesothelioma**
Valerie Rusch, Memorial Sloan Kettering Cancer Center, New York, United States of America

15:30 - 15:50 **Transition to the 10th edition: Open-end!**
Paula Ugalde, Harvard Medical School, Boston, United States of America

15:50 - 16:00 **Q&A and discussion**

14:30 - 16:00 **Type: Educational session** **Congress Hall**
Title: IO in early disease
Moderation: Kersti Oselin, Estonia; Nan Wu, China

14:30 - 14:50 **IO in early disease: Clinical decisions**
Kersti Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, Estonia

14:50 - 15:10 **Assessment of response and surrogate endpoints in perioperative IO trials.**
Nan Wu, Peking University Cancer Hospital and Institute, Beijing, China

15:10 - 15:30 **Biomarker exploration of IO in early disease: Who will benefit and what drives treatment resistance?**
Martin Schuler, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany

15:30 - 15:50 **Combination of IO and emerging new treatments in early disease**
Heather Wakelee, Stanford University, Stanford, United States of America

15:50 - 16:00 **Q&A and discussion**



14:30 - 15:30	Type: Controversy session Title: The pros and cons of PROs Moderation: Rolf Stahel, Switzerland	South Hall 2
14:30 - 14:40	Introduction and first vote <u>Rolf Stahel</u> , ETOP IBCSG Partners Foundation, Bern, Switzerland	
14:40 - 15:00	PROs: We need more <u>Alona Zer</u> , Rambam Health Care Campus, Haifa, Israel	
15:00 - 15:20	PROs: We need to simplify <u>Herbert Ho Fung Loong</u> , The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong PRC	
15:20 - 15:30	Second vote and conclusions/discussion <u>Rolf Stahel</u> , ETOP IBCSG Partners Foundation, Bern, Switzerland	
15:45 - 16:30	Type: Young Oncologists session Title: YO Mentorship session Moderation: Elene Mariamidze, Georgia; Hongcheng Zhu, China; Myrto Moutafi, Greece	Foyer
15:45 - 16:30	Table 1: International collaborations: The great good of clinical advancement? <u>Ross Soq</u> , NCIS - National University Cancer Institute Singapore, Singapore, Singapore	
16:30 - 17:15	Table 2: How to get your first project funding? <u>Marina Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America	
16:00 - 16:30	Type: Coffee break Title: Coffee break	Congress Hall Foyer



16:30 - 18:00	Type: Educational session Title: Overcoming IO resistance Moderation: Myung-Ju Ahn, Korea, Republic of; Milada Zemanova, Czech Republic	Congress Hall
16:30 - 16:50	Mechanism of IO resistance <u>Myung-Ju Ahn</u> , Samsung Medical Center, Seoul, Korea, Republic of	
16:50 - 17:10	Novel co-stimulatory and co-inhibitory drugs (LAG3, TIM3, TIGIT, bispecific, OX-40, 41BB, BiTE etc) <u>Alfredo Addeo</u> , University Hospital of Geneva, Geneva, Switzerland	
17:10 - 17:30	Cytokines and other immune modulators <u>Paola Nisticò</u> , IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy	
17:30 - 17:50	Personalised cancer vaccine and cell therapy <u>Mark Awad</u> , Dana Farber Cancer Institute, Boston, United States of America	
17:50 - 18:00	Q&A and discussion	



16:30 - 17:30		South Hall 2
Type: Mini Oral session		
Title: Mini Oral session 1		
Moderation: Gerard Hanna, United Kingdom; Antonio Passaro, Italy		
16:30 - 16:35	LBA2 - Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study <u>Mark Awad</u> , Dana Farber Cancer Institute, Boston, United States of America	
16:35 - 16:40	194MO - Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results <u>Yan Zhang</u> , West China Medical Center of Sichuan University, Chengdu, China	
16:40 - 16:50	Invited Discussant LBA2 and 194MO <u>Gerard Hanna</u> , Queen's University Belfast, Belfast, United Kingdom	
16:50 - 16:55	Q&A	
16:55 - 17:00	1MO - A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation <u>Yongchang Zhang</u> , Hunan Cancer Hospital, Changsha, China	
17:00 - 17:05	137MO - Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study) <u>Zhang Li</u> , Sun Yat-sen University Cancer Center, Guangzhou, China	
17:05 - 17:10	2MO - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
17:10 - 17:22	Invited Discussant 1MO, 137MO and 2MO <u>Antonio Passaro</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy	
17:22 - 17:27	Q&A	



16:30 - 18:00	Type: Educational session Title: Optimising treatment for special populations Moderation: Alessio Cortellini, Italy; Laura Mezquita, Spain	Forum Hall
16:30 - 16:45	Integrated geriatric assessment and clinical outcomes in patients with lung cancer <u>Carolyn Presley</u> , Ohio State University Medical Center, Columbus, United States of America	
16:45 - 17:00	Performance status versus age <u>Sabine Schmid</u> , Inselspital - Universitätsklinik für Medizinische Onkologie, Bern, Switzerland	
17:00 - 17:15	Polypharmacy and concomitant medications as prognostic factors for immune checkpoint blockade <u>Alessio Cortellini</u> , Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy	
17:15 - 17:30	How to unravel the obesity paradox in lung cancer <u>Sai Yendamuri</u> , Roswell Park Comprehensive Cancer Center, Buffalo, United States of America	
17:30 - 17:45	Exercise in lung cancer: Time to get moving <u>Morten Quist</u> , Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark	
17:45 - 18:00	Q&A and discussion	



18:15 - 19:45	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eli Lilly and Company - Optimising molecular diagnosis and precision therapy in patients with advanced NSCLC harbouring rare oncogenic translocations Moderation: Zofia Piotrowska, United States of America; Antonio Calles Blanco, Spain	Forum Hall
18:15 - 18:25	Welcome and introduction <u>Zofia Piotrowska</u> , MGH - Massachusetts General Hospital, Boston, United States of America	
18:25 - 18:45	Tissue and liquid-based next-generation sequencing diagnostics for patients with advanced NSCLC: Platforms, timings and issues with tissues <u>Antonio Calles Blanco</u> , Hospital General Universitario Gregorio Marañón, Madrid, Spain	
18:45 - 19:05	Molecular Reports in advanced NSCLC: How to optimise report structure, molecular tumour board input and actionability <u>Ales Ryska</u> , University Hospital (Fakultni Nemocnice), Hradec Kralove, Czech Republic	
19:05 - 19:25	Optimal therapeutic regimens for advanced NSCLC patients with rare oncogenic translocations (beyond ALK) and insights on resistance upon retesting <u>Zofia Piotrowska</u> , MGH - Massachusetts General Hospital, Boston, United States of America	
19:25 - 19:40	Q&A and discussion	
19:40 - 19:45	Concluding remarks <u>Antonio Calles Blanco</u> , Hospital General Universitario Gregorio Marañón, Madrid, Spain	



18:15 - 19:45	Type: Industry Satellite Symposium Title: Clinical Care Options, LLC - TROP-2-targeted ADCs for NSCLC: Integrating a new therapeutic option Moderation: David Planchard, France; Helena A. Yu, United States of America	South Hall 2
18:15 - 18:35	Intro Slides <u>David Planchard</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
18:35 - 18:40	Welcome and introduction <u>David Planchard</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
18:40 - 18:55	Role of TROP-2 in NSCLC <u>David Planchard</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
18:55 - 19:25	Latest therapeutic advancements in targeting TROP-2 in NSCLC <u>Helena A. Yu</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America	
19:25 - 19:50	Contemplating the future role of targeting TROP-2 in NSCLC <u>Luis Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
19:50 - 20:05	Panel discussion with audience question and answer session <u>Helena A. Yu</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America	



21.03.2024

08:00 - 09:00 **Type: Multidisciplinary Tumour Board** **Congress Hall**
Title: Controversies in stage I NSCLC
Moderation: Hisao Asamura, Japan; Elene Mariamidze, Georgia

08:00 - 08:10 **Case presentation**
Elene Mariamidze, Todua Clinic, Tbilisi, Georgia

08:10 - 08:25 **When is SBRT a reasonable consideration for stage I NSCLC and should we ever consider adjuvant systemic therapy**
Fiona McDonald, The Royal Marsden Hospital - Chelsea, London, United Kingdom

08:25 - 08:40 **When is surgery the only best approach for stage I NSCLC and when should we consider systemic adjuvant therapy**
Hisao Asamura, Keio University School of Medicine, Shinjuku-ku, Japan

08:40 - 09:00 **Q&A and discussion**

08:00 - 09:00 **Type: Controversy session** **Forum Hall**
Title: Does liquid biopsy have a role in monitoring adjuvant therapy?
Moderation: Natasha Leighl, Canada

08:00 - 08:10 **Introduction and first vote**
Natasha Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada

08:10 - 08:30 **Yes (PRO)**
Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain

08:30 - 08:50 **No (CONTRA)**
Jordi Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, France

08:50 - 09:00 **Second vote and conclusions/discussion**
Natasha Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada



09:15 - 10:45	Type: Educational session Title: ESTS: Defining resectability in locally advanced NSCLC Moderation: Isabelle Opitz, Switzerland; Martin Svaton, Czech Republic	South Hall 2
09:15 - 09:40	The biological view <u>Isabelle Opitz</u> , University Hospital Zürich, Zurich, Switzerland	
09:40 - 10:05	The technical view <u>Clemens Aigner</u> , Medical University Vienna, Vienna, Austria	
10:05 - 10:30	The functional view <u>Alessandro Brunelli</u> , St. James's University Hospital, Leeds, United Kingdom	
10:30 - 10:40	Q&A and discussion	
09:15 - 10:45	Type: Educational session Title: ETOP-IBCSG: Areas under investigation Moderation: Rolf Stahel, Switzerland; Maurice Perol, France	Forum Hall
09:15 - 09:35	Personalized drug therapy for mesothelioma: Do we have enough targets? <u>Alessandra Curioni-Fontecedro</u> , Cantonal Hospital of Fribourg, Fribourg, Switzerland	
09:35 - 09:55	Emerging strategies to overcome osimertinib resistance <u>Ross Soo</u> , NCIS - National University Cancer Institute Singapore, Singapore, Singapore	
09:55 - 10:15	Strategies to improve KRAS inhibition <u>Maurice Perol</u> , Centre Léon Bérard, Lyon, France	
10:15 - 10:35	Lung cancer biomarker harmonisation and validation: Insights from the ETOP Translation Group <u>Stephen Finn</u> , St James's Hospital, Dublin, Ireland	
10:35 - 10:45	Q&A and discussion	



09:15 - 10:45	Type: Educational session Title: ESTRO: Opportunites and challenges in radiation oncology Moderation: Umberto Ricardi, Italy; Fiona McDonald, United Kingdom	Congress Hall
09:15 - 09:35	Contouring of cardiac substructures: From atlas to AI and new dose constraints <u>Kathryn Banfill</u> , Manchester, United Kingdom	
09:35 - 09:55	SABR in central lung tumors <u>Matthias Guckenberger</u> , USZ - University Hospital Zürich, Zurich, Switzerland	
09:55 - 10:15	Chemobeam+IO in stage III NSCLC <u>Umberto Ricardi</u> , Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, Italy	
10:15 - 10:35	Combining radiations with new drugs (TT/IO) in thoracic oncology <u>Dirk De Ruysscher</u> , Maastrro Clinic, Maastricht, Netherlands	
10:35 - 10:45	Q&A and discussion	
10:45 - 11:15	Type: Coffee break Title: Coffee break	Congress Hall Foyer
11:15 - 12:45	Type: Educational session Title: Small cells: Still a big issue Moderation: JUNKO TANIZAKI, Japan; Lizza Hendriks, Netherlands	Forum Hall
11:15 - 11:35	Tumor biology and molecular subtypes of SCLC <u>Carl Gay</u> , MD Anderson Cancer Center, Houston, United States of America	
11:35 - 11:55	New developments in radiation treatment in SCLC <u>Jose Belderbos</u> , Amsterdam, Netherlands	
11:55 - 12:15	Recent advances and challenges: IO in SCLC <u>Junko Tanizaki</u> , Kindai University - Faculty of Medicine, Osaka, Japan	
12:15 - 12:35	Recent advances and challenges: Non-IO approaches in SCLC <u>Martin Frueh</u> , Kantonsspital St. Gallen, St. Gallen, Switzerland	
12:35 - 12:45	Q&A and discussion	



11:15 - 12:15	Type: Multidisciplinary Tumour Board Title: Approaches in N2 Moderation: Giulia Veronesi, Italy; Hongcheng Zhu, China	South Hall 2
11:15 - 11:25	Case presentation <u>Hongcheng Zhu</u> , Fudan University Shanghai Cancer Center, Shanghai, China	
11:25 - 11:40	PACIFIC is the best approach for N2 disease <u>Clara Chan</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom	
11:40 - 11:55	Checkmate 816 is the best approach for N2 disease <u>Giulia Veronesi</u> , IRCCS Ospedale San Raffaele, Milan, Italy	
11:55 - 12:15	Q&A and discussion	
11:15 - 12:45	Type: Educational session Title: IO therapies: Beyond checkpoint inhibitors Moderation: Alona Zer, Israel; Marco Tagliamento, France	Congress Hall
11:15 - 11:35	New and promising checkpoints to block <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	
11:35 - 11:55	Bi-specific Abs in development <u>Daniel Shao Weng Tan</u> , National Cancer Centre Singapore, Singapore, Singapore	
11:55 - 12:15	CAR-T and TCRs for thoracic malignancies <u>Michal Lotem</u> , Hadassah Ein Kerem, Jerusalem, Israel	
12:15 - 12:35	Vaccine-based therapy <u>Marco Tagliamento</u> , Gustave Roussy - Cancer Campus, Villejuif, France	
12:35 - 12:45	Q&A and discussion	



12:45 - 13:30	Type: Young Oncologists session Title: YO Vesalius talk - One size doesn't fit all: How to navigate obstacles in career advancements of lung cancer Moderation: Elene Mariamidze, Georgia; Hongcheng Zhu, China; Myrto Moutafi, Greece	Club A
12:45 - 12:45	Panellist <u>Jarushka Naidoo</u> , Beaumont Hospital, Dublin, Ireland	
12:45 - 12:45	Panellist <u>Alfredo Addeo</u> , University Hospital of Geneva, Geneva, Switzerland	
12:45 - 12:45	Panellist <u>Lizza Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, Netherlands	
12:45 - 12:45	Panellist <u>Herbert Ho Fung Loong</u> , The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, Hong Kong PRC	
13:30 - 15:00	Type: Industry Satellite Symposium Title: Pfizer Oncology - Shaping the future of ALK+ NSCLC: What's the next leap forward? Moderation: Solange Peters, Switzerland	South Hall 2
13:30 - 13:35	Welcome and introduction <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
13:35 - 13:55	Evolution of the 1L ALK+ NSCLC treatment landscape <u>Giulia Pasello</u> , Università degli Studi di Padova, Padova, Italy	
13:55 - 14:20	Optimising patient outcomes <u>Jessica Lin</u> , Massachusetts General Hospital, Boston, United States of America	
14:20 - 14:40	Balancing efficacy with tolerability and quality of life <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
14:40 - 14:55	Pushing boundaries for the next leap forward in ALK+ NSCLC <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
14:55 - 15:00	Meeting close <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	



13:30 - 15:00	Type: Industry Satellite Symposium Title: Janssen Pharmaceutica NV - Guiding clinical decision-making in advanced EGFR-mutant NSCLC Moderation: Martin Reck, Germany; Umberto Malapelle, Italy	Forum Hall
13:30 - 13:50	Intro Video <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	
13:50 - 13:55	Welcome and introductions <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	
13:55 - 14:00	Guiding treatment decision choices: Molecular pathology in EGFR-mutant NSCLC <u>Umberto Malapelle</u> , Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, Italy	
14:00 - 14:15	Navigating the current treatment landscape for common EGFR-mutant NSCLC <u>Raffaele Califano</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom	
14:15 - 14:30	Panel discussion	
14:30 - 14:40	Advances in EGFR exon20ins mutations in NSCLC <u>Pascale Tomasini</u> , Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital La Timone, CEPCM, Marseille, France	
14:40 - 14:55	Panel discussion	
14:55 - 15:15	Living with lung cancer: Implementing shared-decision making with our patients <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	
15:15 - 15:20	Closing remarks <u>Umberto Malapelle</u> , Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, Italy	



15:10 - 16:40	Type: Proffered Paper session Title: Proffered Paper session Moderation: Heather Wakelee, United States of America; Solange Peters, Switzerland	Congress Hall
15:10 - 15:20	40 - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes <u>Natalia Isabel Valdiviezo Lama</u> , INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru	
15:20 - 15:30	Invited discussant 40 <u>Joop De Langen</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
15:30 - 15:35	Q&A	
15:35 - 15:45	1080 - Surgical outcomes from RATIONALE-315: Randomized, double-blind, phase III study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC <u>Dongsheng Yue</u> , TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, China	
15:45 - 15:55	Invited Discussant 1080 <u>Jonathan Spicer</u> , McGill University Health Centre, Montreal, Canada	
15:55 - 16:00	Q&A	
16:00 - 16:10	LBA1 - Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2 <u>Jeffrey Bradley</u> , University of Pennsylvania, Philadelphia, United States of America	
16:10 - 16:20	1930 - Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial <u>Gerard Walls</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom	
16:20 - 16:30	Invited Discussant 193MO and LBA1 <u>Fiona Mcdonald</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
16:30 - 16:40	Q&A	
16:40 - 17:00	Type: Coffee break Title: Coffee break	Congress Hall Foyer



17:00 - 17:50	Type: Mini Oral session Title: Mini Oral session 2	Forum Hall
Moderation: Zofia Piotrowska, United States of America; Hazel O'Sullivan, Ireland		
17:00 - 17:05	3MO - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2 <u>Ryan Gentzler</u> , University Hospital of Virginia (UVA), Charlottesville, United States of America	
17:05 - 17:10	5MO - Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study <u>Maria Rosario Garcia Campelo</u> , University Hospital A Coruña, and Biomedical Research Institute (INIBIC, A Coruña), A Coruña, Spain	
17:10 - 17:20	Invited Discussant 3MO and 5MO <u>Zofia Piotrowska</u> , MGH - Massachusetts General Hospital, Boston, United States of America	
17:20 - 17:25	Q&A	
17:25 - 17:30	6MO - Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study <u>Natasha Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada	
17:30 - 17:35	244MO - Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC <u>Federico Cappuzzo</u> , IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy	
17:35 - 17:45	Invited Discussant 6MO and 244MO <u>Hazel O'Sullivan</u> , CUH - Cork University Hospital, Cork, Ireland	
17:45 - 17:50	Q&A	



17:00 - 18:00	Type: Multidisciplinary Tumour Board Title: Challenges with neo-adjuvant IO Moderation: Isabelle Opitz, Switzerland; Kristof Cuppens, Belgium	Congress Hall
17:00 - 17:10	Case presentation <u>Kristof Cuppens</u> , Jessa Hospital, Hasselt, Belgium	
17:10 - 17:25	Assessing response and clinical benefit after NEOAdjuvant IO: The surgeon perspective <u>Chris Dickhoff</u> , Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, Netherlands	
17:25 - 17:40	Assessing response and clinical benefit after NEOAdjuvant IO: The oncologist perspective <u>Marina Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America	
17:40 - 18:00	Q&A and discussion	
18:15 - 19:45	Type: Industry Satellite Symposium Title: Amgen - Advancing therapeutic strategies in lung cancer care Moderation: Enriqueta Felip, Spain	Forum Hall
18:15 - 18:25	New actionable targets, more potential treatment options <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
18:25 - 18:45	KRASG12C inhibitors: clinical and real-world outcomes in advanced NSCLC <u>Nicolas Girard</u> , Institut Curie, Paris, France	
18:45 - 19:05	DLL3 T cell-engagers: a novel approach for patients with SCLC <u>Fiona Blackhall</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom	
19:05 - 19:25	Patient monitoring and management with T-cell engagers <u>Jurgen Wolf</u> , Universitätsklinikum Köln (AÖR), Cologne, Germany	
19:25 - 19:40	Panel discussion and Q&A	
19:40 - 19:45	Summary and close <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital, Barcelona, Spain	



18:15 - 19:45	Type: Industry Satellite Symposium Title: Regeneron - Current approaches and future strategies in non-oncogene driven advanced NSCLC Moderation: Solange Peters, Switzerland	South Hall 2
18:15 - 18:35	Considerations for immunotherapy in 1L advanced NSCLC <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
18:35 - 18:55	Monotherapy vs. combination therapy treatment considerations <u>Marina Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America	
18:55 - 19:15	Unmet needs and future directions in advanced NSCLC <u>Jarushka Naidoo</u> , Beaumont Hospital, Dublin, Ireland	
19:15 - 19:45	Panel discussion	



22.03.2024

08:15 - 09:15 **Type: Controversy session** **Congress Hall**
Title: Which is most impactful in mesothelioma?
Moderation: Paul Baas, Netherlands

08:15 - 08:25 **Introduction and first vote**
Paul Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, Netherlands

08:25 - 08:45 **Radical / cytoreductive surgery**
Anne Tsao, The University of Texas MD Anderson Cancer Center, Houston, United States
of America

08:45 - 09:05 **Systemic therapy**
Eric Lim, Royal Brompton Hospital, London, United Kingdom

09:05 - 09:15 **Second vote and conclusions/discussion**
Paul Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,
Amsterdam, Netherlands



08:15 - 09:15	Type: Mini Oral session Title: Mini Oral session 3 Moderation: Jessica Menis, Italy; Jelena Spasic, Serbia	Forum Hall
08:15 - 08:20	176MO - Low-dose computed tomography lung cancer screening participants live longer than matched controls: A population-based study <u>Robert Dziedzic</u> , Medical University of Gdansk, Gdansk, Poland	
08:20 - 08:25	177MO - Cardiovascular assessment in lung cancer screening: Initial findings from the European 4-IN-THE-LUNG-RUN trial <u>Daiwei Han</u> , i-DNA B.V., Groningen, Netherlands	
08:25 - 08:35	Invited Discussant 176MO and 177MO <u>Jelena Spasic</u> , Clinic for Urology, Clinical center of Serbia, Belgrade, Serbia	
08:35 - 08:40	Q&A	
08:40 - 08:45	195MO - Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity <u>Horst-Dieter Hummel</u> , University of Würzburg, Wuerzburg, Germany	
08:45 - 08:50	196MO - Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701) <u>Ying Cheng</u> , Jilin Cancer Hospital, Changchun, China	
08:50 - 08:55	197MO - Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group <u>Giannis Mountzios</u> , Henry Dunant Hospital Centre, Athens, Greece	
08:55 - 09:05	Invited Discussant 195MO, 196MO and 197MO <u>Jessica Menis</u> , AOU Integrata di Verona - Ospedale Borgo Roma, Verona, Italy	
09:05 - 09:15	Q&A	



09:30 - 10:00	Type: Keynote lecture Title: The rise of proteomics in never-smokers in lung cancer Moderation: Natasha Leighl, Canada	Congress Hall
09:30 - 09:35	Introduction by the Chair <u>Natasha Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada	
09:35 - 10:00	The rise of proteomics in never-smokers in lung cancer <u>Yu-Ju Chen</u> , Academia Sinica, Taipei City, Taiwan	
10:00 - 10:30	Type: Coffee break Title: Coffee break	Congress Hall Foyer
10:30 - 12:30	Type: Special session Title: Pioneering survivorship excellence (Cancer nursing session) Moderation: Helena Ullgren, Sweden; Melissa Culligan, United States of America	Club A
10:30 - 10:50	Digital symptom monitoring in clinical practice <u>Helena Ullgren</u> , Karolinska University Hospital-Solna, Solna, Sweden	
10:50 - 11:10	Physical activity / Prehab and lung cancer update of the literature <u>Morten Quist</u> , Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark	
11:10 - 11:30	Sexual health and lung cancer <u>Stephanie Ejegi-Memeh</u> , University of Sheffield - School of Nursing and Midwifery, Sheffield, United Kingdom	
11:30 - 11:50	The nursing role in mesothelioma survivorship <u>Melissa Culligan</u> , Temple University Cancer Center, Baltimore, United States of America	
11:50 - 12:10	Mesothelioma palliative care needs: Supporting patients and families with new research-based resource <u>Sarah Hargreaves</u> , University of Sheffield - School of Nursing and Midwifery, Sheffield, United Kingdom	
12:10 - 12:30	Q&A and discussion	



10:30 - 12:00 **Type: Educational session** **Forum Hall**
Title: Moving liquid biopsy forward in the clinic
Moderation: Natasha Leighl, Canada; Umberto Malapelle, Italy

10:30 - 10:50 **Liquid biopsy: Genotyping**
Natasha Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada

10:50 - 11:10 **ctDNA-driven clinical trials in precision immuno-oncology**
Charu Aggarwal, University Of Pennsylvania, Philadelphia, United States of America

11:10 - 11:30 **Next generation technology in liquid biopsy**
Umberto Malapelle, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, Italy

11:30 - 11:50 **Liquid biopsy to monitor minimal residual disease**
Tetsuya Mitsudomi, Kindai University - Faculty of Medicine, Osaka, Japan

11:50 - 12:00 **Q&A and discussion**

10:30 - 11:30 **Type: Controversy session** **South Hall 2**
Title: Stage III: Should we resect or radiate?
Moderation: Giulia Veronesi, Italy

10:30 - 10:40 **Introduction and first vote**
Giulia Veronesi, IRCCS Ospedale San Raffaele, Milan, Italy

10:40 - 11:00 **We should resect**
Jonathan Spicer, McGill University Health Centre, Montreal, Canada

11:00 - 11:20 **We should radiate**
Corinne Faivre-Finn, The Christie NHS Foundation Trust, Manchester, United Kingdom

11:20 - 11:30 **Second vote and conclusions/discussion**
Giulia Veronesi, IRCCS Ospedale San Raffaele, Milan, Italy



10:30 - 12:00 **Type: Educational session** **Congress Hall**
Title: Modulating the IO response with bacteria
Moderation: Lisa Derosa, France; Paul Baas, Netherlands

10:30 - 10:50 **What is microbiome in NSCLC?**
Pieter Hiemstra, LUMC-Leiden University Medical Center, Leiden, Netherlands

10:50 - 11:10 **Is microbiome prognostic or predictive? How can we test it?**
Lisa Derosa, Institut Gustave Roussy, Villejuif, France

11:10 - 11:30 **Can we modulate IO response with microbiome?**
Paul Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

11:30 - 11:50 **Challenges to implement microbiome in clinical trials**
Bertrand Routy, CRCHUM - Centre de recherche du CHUM, Montreal, Canada

11:50 - 12:00 **Q&A and discussion**

12:00 - 12:45 **Type: Poster Display session** **Congress Hall Foyer**
Title: Poster Display session

12:00 - 12:00 **7P - Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC**
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain

12:00 - 12:00 **8P - Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2**
Pascale Tomasini, Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital La Timone, CEPCM, Marseille, France

12:00 - 12:00 **9P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)**
Chee Lee, St George Hospital Cancer Care Centre, Kogarah, Australia

12:00 - 12:00 **10P - Safety and tolerability of first-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: Data from FLAURA2**
Chee Lee, St George Hospital Cancer Care Centre, Kogarah, Australia

12:00 - 12:00 **11P - Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01**
Hidetoshi Hayashi, Kindai University - Faculty of Medicine, Osaka-Sayama, Japan



- 12:00 - 12:00 **12P - Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial**
Martin Frueh, Kantonsspital St. Gallen, St. Gallen, Switzerland
- 12:00 - 12:00 **13P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy**
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
- 12:00 - 12:00 **14P - Consolidative stereotactic radiotherapy in metastatic EGFR-mutant non-small cell lung cancer receiving first-line third-generation EGFR tyrosine kinase inhibitors: A prospective, multicenter, phase II trial**
Yue Zhou, Fudan University Shanghai Cancer Center, Shanghai, China
- 12:00 - 12:00 **15P - Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study**
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
- 12:00 - 12:00 **16P - A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer**
Xiuning Le, The University of Texas M. D. Anderson Cancer Center, Houston, United States of America
- 12:00 - 12:00 **17P - Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs**
Xue Hou, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
- 12:00 - 12:00 **19P - Resistance mechanism to first-line osimertinib in EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) in China: Preliminary data from FLOURISH study**
Jianya Zhou, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
- 12:00 - 12:00 **18P - Preventing CNS metastasis in EGFR-mutant NSCLC patients without baseline CNS metastasis using aumolertinib**
Fang Cun, Nanjing Chest Hospital - Medical School of Southeast University, Nanjing, China
- 12:00 - 12:00 **20P - Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study**
Yuan-Kai Shi, Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, China



- 12:00 - 12:00 **21P - NGS and FISH for MET amplification detection in post EGFR-TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multi-center study in China**
Qian Zheng, SCU - Sichuan University - Huaxi Campus, Chengdu, China
- 12:00 - 12:00 **22P - Evaluation of co-mutation in EGFR-mutant non-small cell lung cancer by next generation sequencing (NGS): Retrospective cohort study in South Korea**
Jiyeon Kim, Asan Medical Center - University of Ulsan, Seoul, Korea, Republic of
- 12:00 - 12:00 **23P - Clinical impact and prognostic value of EGFR mutation co-occurring with ALK, ROS1, RET fusions, or MET exon 14 skipping mutations in Chinese patients with non-small cell lung cancer**
Lili Shen, Affiliated Cancer Hospital of Chongqing University, Chongqing, China
- 12:00 - 12:00 **24P - EGFR PACC mutations occur more frequently in compound than classical mutations with improved responses to TKIs**
Xiuning Le, The University of Texas M. D. Anderson Cancer Center, Houston, United States of America
- 12:00 - 12:00 **25P - Real-world treatment patterns and outcomes in the US after first-line (1L) osimertinib (osi) in patients with epidermal growth factor receptor (EGFR)-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)**
Frank Griesinger, Pius Hospital, Oldenburg, Germany
- 12:00 - 12:00 **26P - Prognostic factors and outcomes of patients (Pts) with advanced NSCLC while on osimertinib (Osi) treatment (Tx): A retrospective database study**
Maurice Perol, Centre Léon Bérard, Lyon, France
- 12:00 - 12:00 **27P - CNS-progression patterns in patients with EGFR-mutant NSCLC receiving standard platinum-based chemotherapy post-osimertinib**
Ilaria Attili, IEO - Istituto Europeo di Oncologia, Milan, Italy
- 12:00 - 12:00 **28P - Long-term survival and treatment (tx) patterns in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced NSCLC treated with first-line (1L) osimertinib (osi): German cohort of a global real-world (rw) observational study**
Frank Griesinger, Pius Hospital, Oldenburg, Germany
- 12:00 - 12:00 **29P - Real-world safety of osimertinib in Chinese patients with non-small cell lung cancer (NSCLC)**
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
- 12:00 - 12:00 **30P - Uncommon EGFR kinase domain mutations and responses to EGFR inhibitors: A systematic review**
Maxime Borgeaud, HUG - Hopitaux Universitaires de Geneve, Geneva, Switzerland
- 12:00 - 12:00 **31P - Myelosuppression risk from epidermal growth factor receptor-tyrosine kinase inhibitors, carboplatin chemotherapy, or both in EGFR mutated non-small**



cell lung cancer (NSCLC)

Nicolas Girard, Institut Curie, Paris, France

- 12:00 - 12:00 **32P - Efficacy and safety of furmonertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: A real-world retrospective study**
Huan Han, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
- 12:00 - 12:00 **33P - Real-world data of furmonertinib for patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations**
Maolin Liu, Sun Yat-sen University Cancer Center, Guangzhou, China, Guangzhou, China
- 12:00 - 12:00 **34P - Updated data from Beamion LUNG-1, a phase (ph) Ia/b trial of the HER2-specific tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631), in patients (pts) with HER2 mutation-positive (m+) NSCLC**
Yi-Long Wu, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China
- 12:00 - 12:00 **35P - Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer**
Oliver Gautschi, Luzerner Kantonsspital, Luzern, Switzerland
- 12:00 - 12:00 **36P - Selpercatinib treatment beyond progression (PD) in RET fusion-positive NSCLC: Association with pattern of PD**
María José De Miguel Luken, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain
- 12:00 - 12:00 **37P - ReAlec interim analysis: An observational study to evaluate the real-world clinical management and outcomes of patients (pts) with advanced ALK+ NSCLC treated with alectinib**
Emilio Brià, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
- 12:00 - 12:00 **38P - Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L**
Angelo Delmonte, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy
- 12:00 - 12:00 **39P - Evaluation of body mass composition (BMC) changes in metastatic ALK-positive non-small cell lung cancer (ALK-mNSCLC) patients treated with anti-ALK tyrosine kinase inhibitors (aALK-TKIs): Preliminary results**
Salvatore Grisanti, University of Brescia, Brescia, Italy
- 12:00 - 12:00 **40P - Lorlatinib-associated weight gain and dyslipidaemia: A single centre UK experience**
Alexius John, The Royal Marsden Hospital - Chelsea, London, United Kingdom



- 12:00 - 12:00 **41P - The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI treated NSCLC patients**
Fenneke Zwierenga, UMCG - University Medical Center Groningen, Groningen, Netherlands
- 12:00 - 12:00 **42P - Development of an online tool for the management of drug-drug interactions with the ROS1/TRK tyrosine kinase inhibitor repotrectinib**
David Burger, Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands
- 12:00 - 12:00 **43P - Updated efficacy and circulating tumour (ct)DNA analysis in patients (pts) with TRK fusion lung cancer treated with larotrectinib (laro)**
Alexander Drilon, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
- 12:00 - 12:00 **44P - Protecting supernatant cfRNA from cytology samples for the detection of fusions in advanced non-small cell lung cancer (NSCLC) patients**
Zheng Wang, Beijing Hospital, Beijing, China
- 12:00 - 12:00 **45P - Actionable mutations in matched liquid and tissue biopsy next-generation sequencing**
Elaine Ko, HKU - The University of Hong Kong, Hong Kong, Hong Kong PRC
- 12:00 - 12:00 **46P - The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study**
Mahmut Yildirim, Istanbul Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey
- 12:00 - 12:00 **47P - Next-generation sequencing using tissue specimen collected with a 1.1 mm-diameter cryoprobe in patients with lung cancer**
Jung Seop Eom, Pusan National University Hospital, Busan, Korea, Republic of
- 12:00 - 12:00 **48P - Real-world clinical utility of next-generation sequencing ctDNA for patients with advanced lung squamous cell carcinoma**
Miguel García Pardo De Santayana, Hospital Universitario Ramon y Cajal, Madrid, Spain
- 12:00 - 12:00 **49P - Perioperative circulating tumor DNA redefines induced oligometastatic non-small cell lung cancer at the molecular level**
Rui Fu, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
- 12:00 - 12:00 **50P - Radiomic features of both primary lung nodules and lymph node metastases on chest CT associated with progression-free survival in advanced non-small cell lung cancer patients**
Mohammadhadi Khorrami, Emory University, Atlanta, United States of America
- 12:00 - 12:00 **51P - Exploring the prognostic value of TP53 mutation in NSCLC in the era of**



precision oncology: A prospective real-world study

Matthew Kin Liang Chiu, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong PRC

- 12:00 - 12:00 **52P - Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)**
Alessandro Leonetti, Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- 12:00 - 12:00 **53P - MET exon 14 skipping mutations in non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database**
Maria Lucia Reale, Ospedale Vito Fazzi - ASL Lecce, Lecce, Italy
- 12:00 - 12:00 **54P - Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression**
Miriam Blasi, Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany
- 12:00 - 12:00 **55P - Differences in response to immune treatment between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer**
Laura Pinto, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
- 12:00 - 12:00 **56P - Prevalence, clinical characteristics, and treatment outcomes of patients with KRAS-mutated non-squamous NSCLC and PD-L1 expression: Real-life data analysis**
Jana Safrankova, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
- 12:00 - 12:00 **57P - Retrospective comparative analysis of KRAS mutations in mNSCLC patients treated with first-line immunotherapy or chemoimmunotherapy**
Sabrina Rossi, Humanitas Mirasole S.p.A. IRCCS, Rozzano, Italy
- 12:00 - 12:00 **58P - Molecular characteristics and prognostic value of homologous recombination deficiency (HRD) in non-small cell lung cancer patients**
Zheng Wang, Beijing Hospital, Beijing, China
- 12:00 - 12:00 **59P - Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial**
Nicolas Girard, Institut Curie, Paris, France
- 12:00 - 12:00 **60P - Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study**
Federico Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, Italy
- 12:00 - 12:00 **61P - First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of Camel phase III study**



Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

- 12:00 - 12:00 **62P - First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial**
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- 12:00 - 12:00 **63P - Treatment-free survival (TFS) in patients (pts) with mNSCLC treated with 1L nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in CheckMate (CM) 9LA**
Martin Reck, LungenClinic Grosshansdorf, Grosshansdorf, Germany
- 12:00 - 12:00 **64P - Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1**
Ana Baramidze, Todua Clinic, Tbilisi, Georgia
- 12:00 - 12:00 **65P - Durvalumab combined with chemotherapy and radiotherapy in patients with oligometastatic non-small cell lung cancer (SABRcure)**
Qiwen Li, Sun Yat-Sen University Cancer Center, Guangzhou, China
- 12:00 - 12:00 **67P - Lesion-based results of the non-small cell lung cancer (NSCLC) subgroup in the ARTIC trial: Abscopal effects in metastasized cancer patients treated with radiotherapy and immune checkpoint inhibition**
Lukas Käsmann, LMU Klinikum der Universität München, Munich, Germany
- 12:00 - 12:00 **68P - Phase II results of ivonescimab (ivo) a novel PD-1/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC)**
Zhang Li, Sun Yat-sen University Cancer Center, Guangzhou, China
- 12:00 - 12:00 **69P - Biomarker-driven TAM RTK inhibitor plus immunotherapy would benefit NSCLC in first-line setting: Implications from phase III ORIENT-11 trial**
Anlin Li, Sun Yat-sen University Cancer Center, Guangzhou, China
- 12:00 - 12:00 **70P - Phase II clinical study of envafolimab combined with recombinant human endostatin and chemotherapy as a first-line treatment for driver gene-negative advanced non-small cell lung cancer**
Shuanghu Yuan, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
- 12:00 - 12:00 **71P - A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NCT03991819)**
Christoher Theriau, Princess Margaret Cancer Centre, Toronto, Canada



- 12:00 - 12:00 **72P - A high-polyphenol dietary intervention to improve response to immune checkpoint blockade for lung cancer via modification of the microbiome**
Daniel Spakowicz, OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, United States of America
- 12:00 - 12:00 **73P - Correlation between diet, microbiome composition and clinical outcomes in patients with non-small cell lung cancer**
Julie Malo, CRCHUM - Centre de recherche du CHUM, Montreal, Canada
- 12:00 - 12:00 **74P - Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study**
Jinji Yang, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
- 12:00 - 12:00 **75P - PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase II umbrella trial (CTONG 1702)**
Si-Yang Liu, Jinan University, Guangzhou, China
- 12:00 - 12:00 **76P - Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells**
Andrea Kakouri, CY-Biobank - University of Cyprus, Aglantzia, Cyprus
- 12:00 - 12:00 **77P - Prognostic and predictive value of soluble PD-1 and PD-L1 in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors**
Nick Syrigos, National & Kapodistrian University of Athens (NKUA), Athens, Greece
- 12:00 - 12:00 **79P - Real-world overall survival after planned alternative dosing for pembrolizumab in the treatment of NSCLC: A nationwide retrospective non-inferiority analysis**
Geeske Grit, The University Medical Center - UMCG, Groningen, Netherlands
- 12:00 - 12:00 **80P - LILRB2 defines a monocyte subset which identifies responders of PD-1/PD-L1 immunotherapy with or without chemotherapy in NSCLC**
Linfeng Luo, Sun Yat-sen University Cancer Center, Guangzhou, China
- 12:00 - 12:00 **81P - Single-cell and bulk RNA sequencing analysis of the pan-cancer immune microenvironment identifies a novel tumor-associated macrophage signature predicting immunotherapy response**
Yan Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
- 12:00 - 12:00 **82P - Longitudinal proteomics and single-cell transcriptomics reveal HDAC3 as an immunotherapy biomarker in advanced non-small cell lung cancer**
Liyuan Dai, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 12:00 - 12:00 **83P - Integrating proteomic gene signature-based machine learning model predicts PD-1 monotherapy response in non-small cell lung cancer**



Xiaoshen Zhang, Shanghai Pulmonary Hospital, Shanghai, China

12:00 - 12:00

84P - The predictive and prognostic value of tumor infiltrating lymphocytes in advanced non-small cell lung cancer

Mai Eissa, Air Force Specialized Hospital, New Cairo, Egypt

12:00 - 12:00

85P - NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors

Valeria Cognigni, Università Politecnica delle Marche, Ancona, Italy

12:00 - 12:00

86P - Artificial intelligence tools to predict early progression of non-small cell lung cancer patients treated with immunotherapy: Preliminary evidence from a single-centre experience of black-box and white-box models pairing

Francesca Rita Ogliari, IRCCS Ospedale San Raffaele, Milan, Italy

12:00 - 12:00

87P - An artificial neural network system to predict the response to sintilimab based on the RNA data of ORIENT-3 study

Tongji Xie, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, China

12:00 - 12:00

88P - Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC

Verena Schlintl, Landeskrankenhaus Salzburg, Salzburg, Austria

12:00 - 12:00

89P - Predictors of real-world (rw) outcomes in patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) treated with pembrolizumab-based maintenance (MT)

Vamsidhar Velcheti, NYU Langone Medical Center and School of Medicine, New York, United States of America

12:00 - 12:00

90P - Real-world (RW) post-progression outcomes and treatment (tx) patterns after first-line (1L) immuno-oncology (IO) regimens in patients (pts) with metastatic (m) NSCLC: CORRELATE

Stephen Liu, Lombardi Cancer Center Georgetown University, Washington, United States of America

12:00 - 12:00

91P - Observational retro-prospective study on immune checkpoint inhibitors (ICIs) treatment duration in patients with advanced non-small cell lung cancer (aNSCLC) (I-STOP study)

Maria Gemelli, IRCCS MultiMedica, Milan, Italy

12:00 - 12:00

92P - A novel R-code approach for efficient irAE identification from medical records of NSCLC patients treated with ICIs

Barliz Waissengrin, Cedars-Sinai Medical Center, Los Angeles, United States of America

12:00 - 12:00

93P - Real-world analysis of first-line maintenance (1LM) immunotherapy (IO) ± pemetrexed for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic



Anna Minchom, ICR - Institute of Cancer Research, London, United Kingdom

- 12:00 - 12:00 **94P - Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression**
Filip Markovic, Pulmonology Clinic, Belgrade, Serbia
- 12:00 - 12:00 **95P - Understanding the real-world (RW) impact of time between treatment regimens on clinical outcomes in patients with metastatic NSCLC previously treated with immunotherapy (IO) in the US community oncology setting**
Alexander Spira, University Hospital of Virginia (UVA), Fairfax, United States of America
- 12:00 - 12:00 **96P - Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens**
Alessia Vendittelli, Policlinico Universitario Campus Bio-Medico, Rome, Italy
- 12:00 - 12:00 **97P - Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy**
Rupesh Kotecha, Miami Cancer Institute - Baptist Health South Florida, Miami, United States of America
- 12:00 - 12:00 **98TiP - Safety and efficacy of aumolertinib combined with anlotinib as 1st-line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation**
Zhan Sheng Jiang, TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 12:00 - 12:00 **99TiP - A randomized phase II study of lazertinib alone versus lazertinib plus bevacizumab for advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking history**
Ahn Beung Chul, NCC - National Cancer Center, Goyang, Korea, Republic of
- 12:00 - 12:00 **101TiP - The efficacy and safety of furmonertinib in advanced NSCLC patients with EGFR mutations and CNS metastases based on ctDNA detection in peripheral blood and CSF (FAITH)**
Xiaoyan Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 12:00 - 12:00 **100TiP - Phase II study of aumolertinib combined with local radiation therapy for EGFR mutated stage IV NSCLC patients with oligometastasis**
Fen Zhao, Shandong Cancer Hospital and Institute, Jinan, China
- 12:00 - 12:00 **106TiP - PULSE, a non-inferiority study of maintenance pembrolizumab at usual or low dose in non-squamous lung cancer**
Jordi Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:00 - 12:00 **102TiP - A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or**



metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mut

Yi-Long Wu, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China

- 12:00 - 12:00 **103TiP - Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreak 202)**
Fabrice Barlesi, Gustave Roussy - Cancer Campus, Villejuif, France
- 12:00 - 12:00 **104TiP - Phase Ib/IIa study of ATR inhibitor tivantinib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies**
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain
- 12:00 - 12:00 **105TiP - Adebrelimab combined with famitinib in the treatment of PD-L1^{high} advanced non-small cell lung cancer with brain metastases: A prospective, single-arm trial (BRAIN-AF01)**
Weiran Xu, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 12:00 - 12:00 **107TiP - Dry powder inhaled cisplatin in stage IV NSCLC: The phase I/IIa CIS-DPI-01 study**
Mariana Brandão, Institute Jules Bordet, Anderlecht, Belgium
- 12:00 - 12:00 **109P - A revised international association for the study of lung cancer grading system in invasive pulmonary adenocarcinoma: The inclusion of invasive mucinous adenocarcinomas**
Hanyue Li, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
- 12:00 - 12:00 **110P - The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma**
Chia Liu, Taipei Veterans General Hospital, Taipei City, Taiwan
- 12:00 - 12:00 **112P - Treatment landscape for stages I-III NSCLC in the United States (US) community setting before and after 2020**
Jessica Donington, The University of Chicago, Chicago, United States of America
- 12:00 - 12:00 **113P - A propensity-based analysis of SBRT and VATS for early-stage lung cancer: A guide to data-driven support and decision-making in a multidisciplinary tumour board**
Olivier Van Kerkhove, KU Leuven - Faculty of Pharmaceutical Sciences, Leuven, Belgium
- 12:00 - 12:00 **114P - Efficacy of perioperative/neoadjuvant immunotherapy combined with chemotherapy: Pooled analysis of specific subgroups in randomized controlled trials**
Yakup Ergün, Batman World Hospital, Batman, Turkey



- 12:00 - 12:00 **115P - Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I-III non-small cell lung cancer with high-grade patterns**
Xiaohan Chen, Ningbo University School of Medicine, Ningbo, China
- 12:00 - 12:00 **116P - A novel lung nodule localization method: Predicting the watershed boundary of target blood vessels with AI simulated dyeing model**
Zihao Chen, Guangdong Lung Cancer Institute, Guangzhou, China
- 12:00 - 12:00 **117P - Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung cancer: Thoracoscopic segmentectomy vs lobectomy**
Rene Petersen, Rigshospitalet, Copenhagen, Denmark
- 12:00 - 12:00 **118P - Role of PD-L1 and pathological complete response (pCR) with neoadjuvant (NEO) or perioperative (PERIOP) immune-checkpoint inhibitors (ICI) and platinum-based chemotherapy (PCT) in resectable non-small cell lung cancer (NSCLC): A systematic review and meta**
Antonio Nuccio, IRCCS Ospedale San Raffaele, Milan, Italy
- 12:00 - 12:00 **119P - The role and mechanism of estrogen receptor beta based on SRSF2 in gender differences of lung adenocarcinoma immunotherapy with anti-PD-1**
Hexiao Tang, Zhongnan Hospital Wuhan University, Wuhan, China
- 12:00 - 12:00 **120P - Circulating exosomal biomarkers as a predictive and prognostic marker in non-metastatic-treated NSCLC**
Ebrucan Bulut, Uludag University - Faculty of Medicine, Bursa, Turkey
- 12:00 - 12:20 **Early stage NSCLC**
- 12:20 - 12:20 **121P - Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC**
Jonathan Spicer, McGill University Health Centre, Montreal, Canada
- 12:20 - 12:20 **122P - Evaluating the predictive accuracy of the Lee Revised Cardiac Risk Index for postoperative complications and survival after robotic-assisted pulmonary lobectomy**
Benjamin Antill, USF Health - University of South Florida, Tampa, United States of America
- 12:20 - 12:20 **123P - Updated safety of perioperative durvalumab for resectable NSCLC in AEGEAN**
Laszlo Urban, Matrahaza University and Teaching Hospital, Matrahaza, Hungary
- 12:20 - 12:20 **124P - Automated measurement of coronary artery calcifications predicts survival in resected stage I lung cancer**



Ugo Pastorino, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

12:20 - 12:20

125P - Preliminary analysis on safety of the DEDALUS phase II trial: Induction chemo-durvalumab followed by reduced-dose radiotherapy and maintenance durvalumab for patients with unresectable stage III NSCLC

Andrea Riccardo Filippi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

12:20 - 12:20

126P - Adjuvant aumolertinib for resected EGFR-mutated stage IA2-IIIa non-small cell lung cancer: Updated results from a multiple-center real-world experience

Qingyi Zhang, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China

12:20 - 12:20

127P - Waning effect of adjuvant EGFR TKIs in resected EGFR-mutated (EGFR-m) NSCLC: A systematic review and meta-analysis of randomized clinical trials (RCTs)

Martina Imbimbo, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

12:20 - 12:20

128TiP - A phase II, two parallel group study of neoadjuvant and adjuvant targeted treatment in NSCLC with BRAF V600 or MET exon 14 mutations

Shen Zhao, State Key Laboratory of Oncology in South China, Guangzhou, China

12:20 - 12:20

129P - FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer

Maria Werner-Wasik, Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, United States of America

12:20 - 12:20

130P - Whole-body PET imaging to study bone metabolism in pre- and post-treatment lung cancer patients

Rucha Ronghe, University of Edinburgh, Edinburgh, United Kingdom

12:20 - 12:20

131P - FDG PET-CT as an imaging biomarker in predicting the molecular profile of treatment-naïve NSCLC

Abhishek Palsapure, TMC - Tata Medical Centre, Mumbai, India

12:20 - 12:20

132P - Enhanced lung nodule malignancy prediction through clinical integration in a deep-learning radiomic model

Antoni Rosell, IGTP - The Institute for Health Science Research Germans Trias i Pujol, Barcelona, Spain

12:20 - 12:40

Imaging and staging

12:40 - 12:40

133P - Development of CT image-based atelectasis simulation and non-invasive lung nodule localization system

Jinwook Hwang, Korea University Ansan Hospital, Ansan, Korea, Republic of



- 12:40 - 12:40 **134P - Predictors of success and complications in electromagnetic navigation bronchoscopy of peripheral lung lesions: A retrospective cohort study**
David Lang, Kepler Universitätsklinikum, Linz, Austria
- 12:40 - 12:40 **135P - Simultaneous noninvasive imaging of LAG-3 and PD-L1 for noninvasive immunotyping in lung cancers**
Lishu Zhao, Shanghai Pulmonary Hospital, Shanghai, China
- 12:40 - 12:40 **136TiP - A cohort study on the diagnosis of benign or malignant lung nodules based on synapse 3D software AI devascularization technique**
Qiang Guo, The Second Affiliated Hospital of Nanchang University, Nanchang, China
- 12:40 - 12:40 **138P - Faecalibacterium prausnitzii enhances tumor response to perioperative nivolumab and chemotherapy**
Alejandro Rodriguez-Festa, Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, Spain
- 12:40 - 12:40 **139P - Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis**
Yuelin Han, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 12:40 - 12:40 **140P - New inflammatory biomarkers in unresectable stage III NSCLC treated with radio-chemotherapy (RCT) followed by durvalumab: Preliminary results of the Neutrality trial**
Emanuela Olmetto, AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
- 12:40 - 12:40 **141P - Integrative radiomic analysis of peri-tumoral and habitat zones for predicting major pathological response to neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A multicenter, retrospective, cohort study**
Wei Huang, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
- 12:40 - 12:40 **142P - AI-based approaches to predict early response in unresectable LA-NSCLC patients undergoing chemoradiation**
Carlo Greco, UCBM - Università Campus Bio-Medico di Roma, Rome, Italy
- 12:40 - 12:40 **143P - Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE)**
Nan Bi, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China
- 12:40 - 12:40 **144P - Preliminary safety and efficacy of iruplinalkib after chemoradiotherapy (CRT) in ALK/ROS1+ unresectable non-small cell lung cancer (NSCLC): Part 1**



results from the INNOVATION study

Lin Wang, Shandong Cancer Hospital and Institute, Jinan, China

- 12:40 - 12:40 **145P - I-SAbR in unresectable LA-NSCLC patients receiving durvalumab in START-NEW-ERA non-randomised phase II trial**
Paola Anselmo, Radiotherapy Oncology Centre "S.Maria" Hospital, Terni, Italy
- 12:40 - 12:40 **146P - Inter-fraction variation of internal target volume of lung tumour with 4D CT and 4D kV CBCT**
Karthick Raja, PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, India
- 12:40 - 12:40 **147P - Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)**
Jurgen Wolf, Universitätsklinikum Köln (AöR), Cologne, Germany
- 12:40 - 12:40 **148P - Neoadjuvant EGFR-TKI combined with chemotherapy improves the complete response rate in operable EGFR-mutant NSCLC patients: A multicenter real-world study**
Wanpu Yan, Peking University Cancer Hospital & Institute, Beijing, China
- 12:40 - 12:40 **149P - POSITION: Characterising risk factors and outcomes in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC) who fail to complete concurrent chemoradiotherapy (cCRT) or progress during or shortly after cCRT**
Giannis Mountzios, Henry Dunant Hospital Centre, Athens, Greece
- 12:40 - 12:40 **150P - Cardioimaging in stage III lung cancer patients undergoing chemoRT: Preliminary CARERT results**
Federico Gagliardi, AOU Seconda Università degli Studi di Napoli (AOU-SUN), Napoli, Italy
- 12:40 - 12:40 **151P - Myocardial strain evaluation with cardiovascular MRI in patients with locally-advanced NSCLC treated with chemotherapy and radiation therapy**
Miguel García Pardo De Santayana, Hospital Universitario Ramon y Cajal, Madrid, Spain
- 12:40 - 12:40 **152P - Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): Interim analysis of a global real-world (RW) study**
Joel Neal, Stanford University School of Medicine, Stanford, United States of America
- 12:40 - 12:40 **153P - Evaluation of chemoradiotherapy-induced radiation pneumonia in non-small cell lung cancer patients with a history of the human coronavirus disease 2019 (COVID-19)**
Ulviyya Nabizade, National Center of Oncology, Baku, Azerbaijan
- 12:40 - 12:40 **154P - Five-year survival and safety outcomes from the START-NEW-ERA non-**



randomised phase II trial

Fabio Arcidiacono, Radiotherapy Oncology Centre "S.Maria" Hospital, Terni, Italy

- 12:40 - 12:40 **155P - Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14**
Sabine Almeida, KSW - Kantonsspital Winterthur, Winterthur, Switzerland
- 12:40 - 12:40 **156P - The impact of the COVID-19 pandemic on the treatment patterns of patients with stage III unresectable non-small cell lung cancer**
Paolo Borghetti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
- 12:40 - 12:40 **157P - Durvalumab impacts progression-free survival but not local control in patients with inoperable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)**
Franz Zehentmayr, Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
- 12:40 - 12:40 **158P - Neoadjuvant treatment in stage III NSCLC: Comparison with NADIM 2 trial as a gold standard**
Francesc Casas, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
- 12:40 - 12:40 **160P - Perioperative and patient reported outcomes of robotic-assisted and video-assisted thoracoscopic surgery for patients with NSCLC receiving neoadjuvant immunotherapy: A real-world cohort study**
Shaowei Wu, Department of Thoracic Surgery, Guangdong Provincial People's Hospital, Guangzhou, China
- 12:40 - 12:40 **159P - Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma**
Jia Liu, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
- 12:40 - 12:40 **161P - Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab (Durva) for locally advanced non-small cell lung cancer (NSCLC): 2-year update from a multicenter prospective observational study (WJOG12019L)**
Akito Hata, Kobe Minimally Invasive Cancer Center, Kobe, Japan
- 12:40 - 12:40 **162TiP - An update on the VIGILANCE study: Developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer**
Ashley Horne, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 12:40 - 12:40 **163P - Decoding the tumor immune microenvironment to unleash effective immunotherapy avenues for epithelioid malignant pleural mesothelioma**
Cara Haymaker, The University of Texas M. D. Anderson Cancer Center, Houston, United States of America
- 12:40 - 12:40 **164P - Circulating cytokines levels as predictive biomarkers in pleural**



mesothelioma: Preliminary data from a prospective translational study

Daniela Scattolin, Azienda Universitaria Ospedaliera di Padova, Padova, Italy

- 12:40 - 12:40 **165P - Tissue genomic profiling of pleural mesothelioma patients treated with immunotherapy: Unraveling genetic alterations and complexity**
Paolo Ambrosini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
- 12:40 - 12:40 **166P - Impact of immunotherapy (IT) on overall survival (OS) of patients with malignant pleural mesothelioma (MPM) adjusted for tumor histology**
Susana Cedres, Vall d'Hebron University Hospital, Barcelona, Spain
- 12:40 - 12:40 **167P - Copy number intratumour heterogeneity in the context of metastatic seeding**
Shania Makker, Queen Mary University of London, London, United Kingdom
- 12:40 - 12:40 **168P - Validation of lung specific and lung molecular graded prognostic assessment score in metastatic NSCLC with brain metastases from India**
Anil Tibdewal, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, India
- 12:40 - 12:40 **169P - Genomic landscape of NSCLC brain metastases and its potential association with TP53 and tumor mutation burden: A territory-wide program in Hong Kong**
Tsz Yeung Kam, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong PRC
- 12:40 - 12:40 **170P - Change in the epidemiology and costs of metastatic lung cancer in France between 2013 and 2021: Observational study using the SNDS**
Gérard De Pouvourville, ESSEC Business school, Cergy, France
- 12:40 - 13:00 **Metastases to and from the lung**
- 13:00 - 13:00 **171P - Systematic review-based treatment algorithm for multidisciplinary treatment of lung cancer bone metastases**
Chai Hong Rim, Korea University, Seoul, Korea, Republic of
- 13:00 - 13:00 **172P - Real-world data of anlotinib for lung cancers with liver metastases in China**
Minglei Zhuo, Peking University Cancer Hospital & Institute, Beijing, China
- 13:00 - 13:00 **173P - Surgery versus stereotactic body radiation therapy as initial treatment for pulmonary oligometastases from colorectal cancer: A propensity score analysis**
Yaqi Wang, Peking University Cancer Hospital and Institute, Beijing, China
- 13:00 - 13:00 **174P - Intracranial (IC) activity of ivonescimab (ivo) alone or in combination with platinum doublet chemotherapy (PC) in patients (Pts) with advanced non-small cell lung cancer (aNSCLC) and brain metastases (BMs)**



Zhang Li, Sun Yat-sen University Cancer Center, Guangzhou, China

- 13:00 - 13:00 **175P - Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study**
Charlene Hoi Lam Wong, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong PRC
- 13:00 - 13:00 **178P - Germline testing in non-small cell lung cancer (NSCLC): Real-world impact of the discovery of germline pathogenic variants (PGV) in the INHERITY LC (ILC) study**
Juan Carlos Laguna Montes, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
- 13:00 - 13:00 **179P - Immunoprecipitation of tumor-associated ctDNA fragments for novel lung cancer liquid biopsy**
Jake Micallef, Belgian Volition SPRL, Isnes, Belgium
- 13:00 - 13:00 **180P - Substantial radiologist workload reduction can be achieved if artificial intelligence is used as a first-read filter at baseline in lung cancer screening**
Harriet Lancaster, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
- 13:00 - 13:00 **181P - Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands**
Krista Van Doorn-Wink, LUMC-Leiden University Medical Center, Leiden, Netherlands
- 13:00 - 13:00 **182P - Evolution of lung cancer mortality in Spain: 1980-2022, a joinpoint analysis**
Alberto Ruano-Ravina, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 13:00 - 13:00 **183P - Improving timeliness of diagnosis of lung cancer patients through implementation of a web-based lung cancer referral pathway**
Zulfiquer Otty, The Townsville Hospital, Douglas, Australia
- 13:00 - 13:00 **184P - A framework to support implementation of low-dose computed tomography (LDCT) lung cancer screening: Research methodology and opportunities for impact**
Helena Wilcox, The Health Policy Partnership, London, United Kingdom
- 13:00 - 13:00 **185P - Cost and impact assessment of AI-enhanced image analysis in lung cancer screening**
Harriet Lancaster, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
- 13:00 - 13:00 **186P - Impact of poverty and depopulation on the survival of patients with metastatic non-small cell lung cancer**
Luis Posado-Domínguez, University Hospital of Salamanca, Salamanca, Spain



- 13:00 - 13:00 **189P - Lung cancer in young adults, age < 45 years: Clinical characteristics, treatment, histological and molecular features**
Xavier Fremand, Sorbonne Université, Paris, France
- 13:00 - 13:00 **190P - Prevalence of germline variants in Indian non-small cell lung cancer patients with family history of cancer**
Abhay Rastogi, AIIMS - All India Institute of Medical Sciences, New Delhi, India
- 13:00 - 13:00 **191P - Impact of perifissural nodules on lung cancer screening with AI as the initial reader**
Daiwei Han, i-DNA B.V., Groningen, Netherlands
- 13:00 - 13:00 **198P - Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial**
Ying Cheng, Jilin Cancer Hospital, Changchun, China
- 13:00 - 13:00 **199P - Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)**
Mohammadhadi Khorrami, Emory University, Atlanta, United States of America
- 13:00 - 13:00 **201P - Efficacy of carboplatin-etoposide rechallenge after first-line chemoimmunotherapy in ES-SCLC: An international multicentric analysis**
Martin Igor Gomez-Randulfe Rodriguez, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 13:00 - 13:00 **202P - Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC**
Victoria Andreas, Peter MacCallum Cancer Center, Melbourne, Australia
- 13:00 - 13:00 **203P - Treatment patterns and real-world outcomes of extensive-stage small cell lung cancer: A retrospective, multicenter study**
Massimiliano Cani, Università Degli Studi Di Torino - Orbassano, Orbassano, Italy
- 13:00 - 13:00 **204P - Maintenance of anti-tumour innate immune response in SCLC with DNA-PK inhibition**
Caterina De Rosa, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
- 13:00 - 13:00 **205P - Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small cell lung cancer**
Liang Shi, Beijing Chest Hospital, Capital Medical University, Beijing, China
- 13:00 - 13:00 **206P - Liver kinase B1 expression is associated with improved overall survival and decreased CD8+ tumor infiltrating lymphocytes in small cell lung cancer**
Alessandro Dal Maso, IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy



- 13:00 - 13:00 **207P - Lurbinectedin induces multimodal immune activation and augments the anti-tumor immune response in small cell lung cancer**
Triparna Sen, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 13:00 - 13:00 **208P - The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC**
Luca Marzano, KTH Royal Institute of Technology, Stockholm, Sweden
- 13:00 - 13:00 **209P - Small cell lung cancer in never smokers: A descriptive analysis**
Alberto Ruano-Ravina, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 13:00 - 13:00 **210P - Prophylactic cranial irradiation (PCI) in patients with limited-stage small cell lung cancer (LS-SCLC) in the era of magnetic resonance imaging surveillance: A systematic review and meta-analysis**
Lukas Käsmann, LMU Klinikum der Universität München, Munich, Germany
- 13:00 - 13:00 **211P - Transcriptional and epigenetic landscape of neuroendocrine transformation during emergence of resistance to targeted therapies in EGFR mutant lung adenocarcinoma**
Triparna Sen, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 13:00 - 13:00 **212P - Correlation of 68Ga-SSO120 PET with SSTR2 expression and prognostic value in patients with small cell lung cancer**
Ilektra Mavroeidi, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany
- 13:00 - 13:00 **213P - Comprehensive genomic atlas of small cell lung cancer finds PKD1L1 mutation associated with poor prognosis and drug susceptibility**
Haiyong Wang, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
- 13:00 - 13:00 **214TiP - Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774)**
Horst-Dieter Hummel, University of Würzburg, Wuerzburg, Germany
- 13:00 - 13:00 **215TiP - A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT): DURVALUNG trial**
Elisa Gobbini, Institut Curie, Paris, France
- 13:00 - 13:00 **216TiP - A phase II study of consolidation serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer (ASTRUM-LC01)**
Yuqi Wu, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 13:00 - 13:00 **218P - DSG2+ cancer stem cells co-located with POSTN+ myofibroblasts in the**



tumor boundary that determines the efficacy of immunotherapy in non-small cell lung cancer

Guangyu Fan, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

- 13:00 - 13:00 **219P - Leveraging gut metagenomic k-mer signature for the development of a practical and robust model to predict immunotherapy response in NSCLC**
Jun Zhang, KUMC - University of Kansas Medical Center, Kansas City, United States of America
- 13:00 - 13:00 **220P - Advancing lung adenocarcinoma treatment: Establishing KRAS-driven organoids for drug screening**
Isa Tas, Lund University, Lund, Sweden
- 13:00 - 13:00 **221P - Single-cell transcriptomics reveals CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small cell lung cancer**
Yaokai Wen, Guangzhou Medical University, Guangzhou, China
- 13:00 - 13:00 **222P - Mutational variant allele frequency profile as a biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer**
Ruyun Gao, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 13:00 - 13:00 **224P - Cerebrospinal fluid-based mutation abundance index (MAI) correlated to clinical outcome in leptomeningeal metastasis of non-small cell lung cancer with EGFR mutations**
Wenjie Zhu, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 13:00 - 13:00 **225P - The potential synergistic mechanism of the combination of osimertinib and furmonertinib (3+3 mode): Evidence from an in vitro experimental study and structural modeling**
Wenhua Liang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
- 13:00 - 13:20 **Translational research**
- 13:20 - 13:20 **226P - The PerMediNA initiative: A pilot precision oncology project on lung cancer in North Africa**
Yosr Hamdi, IPT - Institut Pasteur de Tunis, Tunis, Tunisia
- 13:20 - 13:20 **227P - Sexual dimorphism in immune profile of early and advanced NSCLC**
Giulia Mazzaschi, University of Parma, Parma, Italy
- 13:20 - 13:20 **228P - SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant**



lung adenocarcinomas through the induction of TGF β signaling

Alvaro Quintanal-Villalonga, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America

- 13:20 - 13:20 **229P - Clinicopathologic and genomic features of patients with mucinous lung adenocarcinoma and response to systemic therapies**
Alessandro Di Federico, AOU Policlinico S. Orsola-Malpighi, Bologna, Italy
- 13:20 - 13:20 **230P - Clinicopathologic and molecular features of STK11-mutated NSCLC**
Pei Li Stephanie Saw, NCCS - National Cancer Centre Singapore, Singapore, Singapore
- 13:20 - 13:20 **231P - Cancer-associated fibroblast-expressed nicotinamide N-methyltransferase is negatively associated with metastasis of lung adenocarcinomas**
Peiyu Wang, Peking University People's Hospital, Beijing, China
- 13:20 - 13:20 **232P - Tumor spread through air spaces is an independent predictor of recurrence-free survival in patients with resected pulmonary lymphoepithelial carcinoma**
Pei-Hsing Chen, National Taiwan University Hospital Hsin - Chu Branch, Hsinchu City, Taiwan
- 13:20 - 13:20 **234P - Clinical findings and genomic characterization of NRG-1 alterations with a comprehensive genome profiling (CGP) in advanced non-small cell lung cancer (ANSCLC)**
Emanuele Vita, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 13:20 - 13:20 **233P - Predictive value of immunohistochemistry assessment of mutated p53 for response and survival outcomes in patients with lung squamous cell cancer following neoadjuvant immunochemotherapy**
Xuhua Huang, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
- 13:20 - 13:20 **235P - Baseline values of circulating nucleosomes in non-small lung cancer (NSCLC): ONCOPRO_LUNG study**
Sebastien Couraud, CICLY - Centre pour l'Innovation en Cancérologie de Lyon - Université Lyon 1-EA 3738, Oullins, France
- 13:20 - 13:20 **236P - INTENT study: Assessment of fast track (FT) panel with IHC, RT-PCR and FISH as an alternative or rescue to NGS panel testing failure in NSCLC**
Pedro Rafael De Marchi, Onco Clinica Raioterapia - Botafogo, Botafogo, Brazil
- 13:20 - 13:20 **237P - Genomic profiling of aggressive pathologic features in lung adenocarcinoma**
Lin Yiduo, Guangdong Provincial People's Hospital, Guangzhou, China
- 13:20 - 13:20 **238P - Mutational patterns in lung cancer: Insights from a nationwide database**



in Israel

Ilit Turgeman, Haemek Medical Center, Afula, Israel

- 13:20 - 13:20 **240P - Feasibility of detecting NSCLC-associated fusion genes in long-term preserved FFPE samples**
Dongmei Lin, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 13:20 - 13:20 **241P - Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors**
Linda N. Lin, Zai Lab (US) LLC, Cambridge, United States of America
- 13:20 - 13:20 **239P - The new IASLC grading system for invasive lung adenocarcinoma predicts the prognosis of patients receiving neoadjuvant immunotherapy**
Haijie Xu, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
- 13:20 - 13:20 **242P - Prognostic role of tumor microenvironment features in advanced non-small cell lung cancer molecular subtypes: A multicentric, retrospective study**
Lodovica Zullo, Institut Gustave Roussy, Villejuif, Cedex, France
- 13:20 - 13:20 **243P - FOXP4 promotes lung cancer cell proliferation and invasion by regulating tumor-associated macrophage polarization through the β -catenin/FOSL2/ARID5A signaling pathway**
Qin Yan, Chengdu Fifth People's Hospital - West District, Chengdu, China
- 13:20 - 13:20 **245P - Age-adjusted trends of pulmonary large cell neuroendocrine carcinoma**
Amr Aly, Suez Canal University Hospital, Ismailia, Egypt
- 13:20 - 13:20 **246P - Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis**
Iris Van Der Sar, Erasmus MC - Erasmus University Rotterdam, Rotterdam, Netherlands
- 13:20 - 13:20 **247P - Real-world evidence of immune checkpoint inhibitor treatment in lung cancer patients from a Belgian multicenter study**
Vincent Geldhof, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 13:20 - 13:20 **249P - Analysis of clinical and prognostic characteristics of patients with lung cancer and solid organ transplantation**
Marta Martinez Cutillas, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain
- 13:20 - 13:20 **250P - Taurolidine as an adjunct in the management of pleural effusion and air leakage after pulmonary resection: A randomized controlled trial**
Chun-Sung Byun, Yonsei University College of Medicine - Wonju Severance Christian Hospital, Wonju, Korea, Republic of



- 13:20 - 13:20 **251P - Sexual dysfunction in patients with lung cancer: Interim analysis of the LUDICAS study**
Aylen Vanessa Ospina Serrano, Fundacion Sta Fe de Bogota Instituto de Oncologia, Bogota, Colombia
- 13:20 - 13:20 **252P - Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project**
Aylen Vanessa Ospina Serrano, Fundacion Sta Fe de Bogota Instituto de Oncologia, Bogota, Colombia
- 13:20 - 13:20 **253P - Digital decision support for structural improvement of lung cancer tumor boards: Using standard cases to optimize workflow**
Carolin Gross-Ophoff-Mueller, Kliniken der Stadt Köln gGmbH, Köln, Germany
- 13:20 - 13:20 **254TiP - A phase I clinical trial testing the dose escalation and expansion of pressurized intrathoracic hyperthermic aerosol cisplatin administration (PITHAC) for the management of pleural carcinosis**
Jean Yannis Perentes, UNIL - University of Lausanne, Lausanne, Switzerland
- 13:20 - 13:20 **255TiP - [DREAM] Double lung transplant registry aimed for lung-limited malignancies: A prospective registry study for medically refractory cancers**
Liam Il-Young Chung, Northwestern University Feinberg School of Medicine, Chicago, United States of America
- 12:45 - 14:15 Type: Industry Satellite Symposium** **South Hall**
Title: Daiichi Sankyo - Targeting rare mutations in NSCLC: A focus on HER2m **2**
Moderation: Egbert Smit, Netherlands
- 12:45 - 12:55 **Welcome and introduction**
Egbert Smit, LUMC-Leiden University Medical Center, Leiden, Netherlands
- 12:55 - 13:15 **Small numbers, big impact: The importance of testing for rare mutations in mNSCLC**
Luka Brcic, Medical University of Graz, Graz, Austria
- 13:15 - 13:35 **The evolving treatment landscape for rare mutations: Focus on HER2m**
Sonja Loges, UMM - Universitaetsklinikum Mannheim, Mannheim, Germany
- 13:35 - 13:55 **Safety considerations for ADCs**
Egbert Smit, LUMC-Leiden University Medical Center, Leiden, Netherlands
- 13:55 - 14:15 **Audience Q&A and closing remarks**
Egbert Smit, LUMC-Leiden University Medical Center, Leiden, Netherlands



12:45 - 14:15 **Type: Special session** **Club A**
Title: Advances in the lung cancer pathway (Patient advocacy session)
Moderation: Anne-Marie Baird, Ireland; JORDI REMON MASIP, France

12:45 - 13:05 **New approaches to augment early detection**
Anne-Marie Baird, St. James's Hospital, Dublin, Ireland

13:05 - 13:25 **Liquid biopsy: Where are we?**
Jordi Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, France

13:25 - 13:45 **New kids on the block: Treatments and technologies**
Sanjay Popat, The Royal Marsden NHS Trust, London, United Kingdom

13:45 - 14:05 **Real world impact of innovations in the care pathway**
Nicoline Ehrhardt, Hannover, Germany

14:05 - 14:15 **Q&A and discussion**



12:45 - 14:15	Type: Industry Satellite Symposium Title: AstraZeneca - From paper to practice: Exploring advances in early-stage NSCLC Moderation: Luis Paz-Ares, Spain	Forum Hall
12:45 - 12:55	Welcome and introduction <u>Luis Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
12:55 - 13:10	Patient case 1: A patient with resectable NSCLC, EGFRm positive <u>Milada Zemanova</u> , VFN - General University Hospital in Prague, Prague, Czech Republic	
13:10 - 13:20	Panel discussion and audience Q&A	
13:20 - 13:35	Patient case 2: A patient with resectable NSCLC, no known actionable mutations <u>Cecilia Pompili</u> , University of Leeds - Institute of Cancer and Pathology (LICAP), Hull, United Kingdom	
13:35 - 13:45	Panel discussion and audience Q&A	
13:45 - 14:00	Patient case 3: A patient with unresectable stage III NSCLC <u>Matthias Guckenberger</u> , USZ - University Hospital Zürich, Zurich, Switzerland	
14:00 - 14:10	Panel discussion and audience Q&A	
14:10 - 14:15	Summary and close <u>Luis Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
14:30 - 15:00	Type: Keynote lecture Title: Incorporating ctDNA and other plasma-based assays into clinical trial design Moderation: Natasha Leighl, Canada	Congress Hall
14:30 - 14:55	Incorporating ctDNA and other plasma-based assays into clinical trial design <u>Maximilian Diehn</u> , Stanford University, Stanford, United States of America	



15:10 - 16:40 **Type: Educational session** **Congress Hall**
Title: AI application in diagnosis and pathology
Moderation: Teodora Radonic, Netherlands; Reinhard Buttner, Germany

15:10 - 15:30 **AI-based tools for differential diagnosis of lung nodules**
Reinhard Buttner, Cologne, Germany

15:30 - 15:50 **Are we there yet? The next wave of AI**
Teodora Radonic, Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, Netherlands

15:50 - 16:10 **AI for diagnosis and predictive biomarkers in thoracic oncology**
Paul Hofman, CHU Nice - Hopital Pasteur, Nice, France

16:10 - 16:30 **Prediction of mutation patterns in lung cancer**
Iris Barshack, Sheba Tel Hashomer Medical Center, Ramat Gan, Israel

16:30 - 16:40 **Q&A and discussion**

15:10 - 16:40 **Type: Educational session** **Forum Hall**
Title: Best therapies with driver mutations in lung cancer
Moderation: Joop De Langen, Netherlands; Zofia Piotrowska, United States of America

15:10 - 15:30 **Optimising first-line treatment strategies in driver-positive lung cancer**
Pilar Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, Spain

15:30 - 15:50 **Common themes in targeted therapy resistance across oncogene-driven NSCLC**
Sun Min Lim, Yonsei Cancer Center Yonsei University, Seoul, Korea, Republic of

15:50 - 16:10 **New targets, new drugs: Promising therapies for KRAS (including non-G12C mutations), HER2, NRG1 and other new targets**
Joop De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

16:10 - 16:30 **How can we optimise the use of immunotherapy for driver+ NSCLC: Are all targets the same?**
Tony S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, Hong Kong PRC

16:30 - 16:40 **Q&A and discussion**



15:10 - 16:40	Type: Special session Title: Challenges of brain metastases: The patient's perspective (Patient advocacy session) Moderation: Shani Shilo, Israel; Matthias Guckenberger, Switzerland	Club A
15:10 - 15:30	Impact of brain metastases on quality of life <u>Debra Montague</u> , ALK Positive UK - Virgin Money Giving, Lightwater, United Kingdom	
15:30 - 15:50	What can patient organisations do to address the impact of brain metastases? <u>Shani Shilo</u> , Israel Lung Cancer Association, Rehovot, Israel	
15:50 - 16:10	Advances in targeting brain metastases <u>Matthias Guckenberger</u> , USZ - University Hospital Zürich, Zurich, Switzerland	
16:10 - 16:30	Clinical trials: Time for broader inclusion criteria? <u>Rafal Dziadziuszko</u> , Medical University of Gdansk, Gdansk, Poland	
16:30 - 16:40	Q&A and discussion	
15:10 - 16:10	Type: Controversy session Title: Using immunotherapy with immunosuppression? Moderation: Sonja Loges, Germany	South Hall 2
15:10 - 15:20	Introduction and first vote <u>Sonja Loges</u> , UMM - Universitaetsklinikum Mannheim, Mannheim, Germany	
15:20 - 15:40	Worth trying <u>Michel Obeid</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
15:40 - 16:00	Not recommended <u>David Pinato</u> , Imperial College London - Hammersmith Hospital, London, United Kingdom	
16:00 - 16:10	Second vote and conclusions/discussion <u>Sonja Loges</u> , UMM - Universitaetsklinikum Mannheim, Mannheim, Germany	
16:40 - 17:00	Type: Coffee break Title: Coffee break	Congress Hall Foyer



17:00 - 18:30	Type: Young Oncologists session Title: YO Clinical cases discussion Moderation: Elene Mariamidze, Georgia; Hongcheng Zhu, China; Myrto Moutafi, Greece	Club A
17:00 - 17:03	Introduction	
17:03 - 17:13	Clinical case 1: Advanced Rare mutations - ALK, ROS1, RET, HER2 and BRAF <u>Alessandro Scala</u> , Roma, Italy	
17:13 - 17:23	Expert discussant - Panel discussion <u>Umberto Malapelle</u> , Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli, Italy	
17:23 - 17:33	Clinical case 2: Primary resistance to immunotherapy <u>Ilit Turgeman</u> , Haemek Medical Center, Afula, Israel	
17:33 - 17:43	Expert discussant - Panel discussion <u>Noemi Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
17:43 - 17:53	Clinical case 3: Brain mets <u>David McMahon</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
17:53 - 18:03	Expert discussant - Panel discussion <u>Antonin Levy</u> , Gustave Roussy - Cancer Campus, Villejuif, France	
18:03 - 18:30	Q&A and discussion	



17:00 - 18:30 **Type: Educational session** **Congress Hall**
Title: Advancing molecular diagnosis in lung cancer
Moderation: Christine Lovly, United States of America; Keith Kerr, United Kingdom

17:00 - 17:25 **Current diagnostic standards for NSCLC: Clinical implications**
Keith Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, United Kingdom

17:25 - 17:50 **How to distinguish primary tumor from metastatic or new primary: Where and how can molecular tools help?**
Sanja Dacic, Yale University School of Medicine, New Haven, United States of America

17:50 - 18:15 **Challenges of the MTB: The flow of molecular testing**
Sonja Loges, UMM - Universitaetsklinikum Mannheim, Mannheim, Germany

18:15 - 18:30 **Q&A and discussion**

17:00 - 18:30 **Type: Educational session** **South Hall 2**
Title: New frontiers in thymoma
Moderation: Nicolas Girard, France; Anja Roden, United States of America

17:00 - 17:20 **The ITMIG/IASLC thymic nodal map: A re-assessment after the 9th TNM for an optimal pre-treatment stage**
Edith Marom, Chaim Sheba Medical Center, Ramat Gan, Israel

17:20 - 17:40 **Complete resection in thymic tumors: How far the surgeons may push surgery?**
Paul Van Schil, UZA - University Hospital Antwerp, Edegem, Belgium

17:40 - 18:00 **Controversies in the histologic definitions of the T component in thymic tumors**
Anja Roden, Mayo Clinic - Rochester, Rochester, United States of America

18:00 - 18:20 **Immunotherapy (IO) and targeted therapy in thymic tumors: What's new?**
Nicolas Girard, Institut Curie, Paris, France

18:20 - 18:30 **Q&A and discussion**



17:00 - 18:30	Type: Educational session Title: Oligometastases: New insights Moderation: Anne-Marie Dingemans, Netherlands; Nan Wu, China	Forum Hall
17:00 - 17:20	The fundamental role and updates of systemic therapy in oligometastatic NSCLC <u>Miguel García Pardo De Santayana</u> , Hospital Universitario Ramon y Cajal, Madrid, Spain	
17:20 - 17:40	Metastasis-directed therapy for oligometastasis: Technological advances and applications <u>Fernando Gomez-Munoz</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
17:40 - 18:00	Dilemma and decision: Local consolidative therapy for oligometastasis <u>Fengming Kong</u> , the University of Hong Kong, HK, China	
18:00 - 18:20	Oligometastasis: What lessons have been learned <u>Anne-Marie Dingemans</u> , Erasmus MC Cancer Institute - Erasmus University Rotterdam, Rotterdam, Netherlands	
18:20 - 18:30	Q&A and discussion	



18:45 - 20:15	Type: Industry Satellite Symposium Title: Seagen - Moving forward in metastatic NSCLC: The role of ADCs Moderation: Martin Reck, Germany	South Hall 2
18:45 - 18:50	Welcome and introduction <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	
18:50 - 19:10	From the current status to unmet needs <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	
19:10 - 19:35	ADCs in late-stage development: Who can benefit? <u>Enriqueta Felip</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
19:35 - 19:55	Beyond the horizon: Unveiling novel ADC targets <u>Anna Minchom</u> , ICR - Institute of Cancer Research, London, United Kingdom	
19:55 - 20:10	Panel discussion and audience Q&A	
20:10 - 20:15	Closing remarks <u>Martin Reck</u> , LungenClinic Grosshansdorf, Grosshansdorf, Germany	



18:45 - 20:15	Type: Industry Satellite Symposium Title: Thermo Fisher Scientific - The critical role of timely genomic profiling in NSCLC Moderation: Fernando Lopez-Rios, Spain	Forum Hall
18:45 - 18:50	Welcome and introduction <u>Fernando Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
18:50 - 19:10	Navigating NSCLC: Oncologists' perspective on biomarker testing needs <u>Francesco Passiglia</u> , Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy	
19:10 - 19:30	When tissue is the issue: Optimising rapid liquid biopsy testing in NSCLC <u>Fernando Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
19:30 - 19:45	Insights from in-house: evaluating the impact of ultra-fast NGS on patient outcomes <u>Morten Grauslund</u> , Rigshospitalet, Copenhagen, Denmark	
19:45 - 20:05	Q&A and panel discussion	
20:05 - 20:10	Closing remarks <u>Fernando Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	



23.03.2024

08:00 - 09:30	Type: Industry Satellite Symposium Title: AstraZeneca - Navigating the metastatic NSCLC treatment landscape: Addressing hard-to-treat tumours Moderation: Sanjay Popat, United Kingdom	South Hall 2
----------------------	--	---------------------

08:00 - 08:10 **Welcome and introduction**

Sanjay Popat, The Royal Marsden NHS Trust, London, United Kingdom

08:10 - 08:25 **Overcoming limitations with first-line immunotherapy in mNSCLC**

Stephen Liu, Lombardi Cancer Center Georgetown University, Washington, United States of America

08:25 - 08:35 **Panel discussion and audience Q&A**

08:35 - 08:50 **Managing the treatment of NSCLC with CNS metastases: Considerations and challenges**

Julia Rotow, The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, United States of America

08:50 - 09:00 **Panel discussion and audience Q&A**

09:00 - 09:15 **Improving the benefit in post-progression mNSCLC**

Sanjay Popat, The Royal Marsden NHS Trust, London, United Kingdom

09:15 - 09:30 **Panel discussion and audience Q&A**



10:00 - 11:30 **Type: Educational session** **Forum Hall**
Title: ADCs: The new promising therapy?
Moderation: Jarushka Naidoo, Ireland; Solange Peters, Switzerland

10:00 - 10:20 **ADCs in Thoracic Oncology: Current Standards and Lessons Learned**
Egbert Smit, LUMC-Leiden University Medical Center, Leiden, Netherlands

10:20 - 10:40 **Toxicities of ADCs**
Jarushka Naidoo, Beaumont Hospital, Dublin, Ireland

10:40 - 11:00 **Predictive biomarkers of ADCs**
Ignacio Wistuba, MD Anderson Cancer Center, Houston, United States of America

11:00 - 11:20 **Novel ADC targets and combination approaches**
Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

11:20 - 11:30 **Q&A and discussion**

10:00 - 11:30 **Type: Educational session** **South Hall 2**
Title: Screening, vaping and smoking cessation: Is it worth it?
Moderation: Laura Mezquita, Spain; Sebastien Couraud, France

10:00 - 10:20 **Is it time to individualise lung cancer screening?**
Sebastien Couraud, CICLY - Centre pour l'Innovation en Cancérologie de Lyon -
Université Lyon 1-EA 3738, Oullins, France

10:20 - 10:40 **Improving lung cancer screening: New technologies**
Lecia Sequist, Massachusetts General Hospital, Boston, United States of America

10:40 - 11:00 **Smoking cessation in lung cancer**
Boris Duchemann, Hôpital Avicenne, Bobigny, France

11:00 - 11:20 **Lung cancer prevention beyond smoking**
Laura Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

11:20 - 11:30 **Q&A and discussion**



11:45 - 13:15	Type: Educational session Title: New biomarkers in NSCLC beyond immunotherapy Moderation: Sanjay Popat, United Kingdom	Forum Hall
11:45 - 12:05	New pathways including FGFR <u>Noemi Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, Spain	
12:05 - 12:25	Biology of STK11 and KEAP1 in NSCLC <u>Antonio Calles Blanco</u> , Hospital General Universitario Gregorio Marañón, Madrid, Spain	
12:25 - 12:45	Beyond G12C: Other RAS / RAF mutation in NSCLC <u>Sanjay Popat</u> , The Royal Marsden NHS Trust, London, United Kingdom	
12:45 - 12:55	Q&A and discussion	
11:45 - 12:45	Type: Multidisciplinary Tumour Board Title: CNS mets: Oncogene addicted and non-oncogene addicted Moderation: Antonin Levy, France; Francesco Cortiula, Italy	South Hall 2
11:45 - 11:55	Case presentation <u>Francesco Cortiula</u> , Udine, Italy	
11:55 - 12:10	Immunotherapy and targeted therapy options for NSCLC brain metastases <u>Lizza Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, Netherlands	
12:10 - 12:25	Integration of local therapy into systemic treatment for NSCLC brain metastases <u>Antonin Levy</u> , Gustave Roussy - Cancer Campus, Villejuif, France	
12:25 - 12:45	Q&A and discussion	



-
Moderation: Melissa Culligan, United States of America